特种通用药物市场[逐施（肿瘤，传染病，多发性硬化症，丙型肝炎，其他）;通过给药途径（口服，肠胃外，局部，注射，其他）;通过分销渠道（零售药房，医院药房，在线药店）;按地区]：市场规模和预测，2018年 - 2025年

报告摘要

全球专业仿制药市场estimated to grow at a CAGR of 25.5% from 2018 to 2025. Specialty Generics drugs are the generic forms of pharmaceutical products. These drugs are economical when compared with branded pharmaceuticals. These drugs include complex molecules, biopharmaceuticals, and blood-derived products. Companies are entering into this market to manufacture generic forms of the products by forming new drug formulations as a number of specialty drug molecules are approaching patent in the upcoming years. Additionally, global capacity of conventional or traditional generics drugs market is also forcing companies to seek newer opportunities. Nonetheless, development and commercialization of specialty generics drug are more complex when compared with conventional generics drugs.

yabo娱乐vip由于昂贵的药物产品，医疗费用增加了，因此，政府正在施加药品制造商生产成本效益的药物。癌症的普遍性是增强全球特色普通药物市场增长的主要因素之一。据国家癌症研究所称，每年在美国每年诊断大约1600万个癌症，导致大约一百万人死亡导致各种类型的癌症发生。此外，特产药物专利未货期，付款人减少药物价格的压力，缺乏仿制药来治疗复杂的疾病，以及有利的报销政策是在预测期间预期的其他因素升起了对特殊仿制药的需求。

Augmentation in the number of off-patent specialty drugs is factor estimated to propel the significant growth of the specialty generic drugs market. For instance, the patent for Novartis drug Gilenya is estimated to expire in 2019. This drug has made approximately 14% sales growth of Novartis. Such early patent expirations are expected to boost the global market growth. North America is the highest spending region in healthcare, yet, this region recently began cutting healthcare expenditure. The current economic & financial crisis and the existence of a high geriatric population are some of the key reasons for the cost cut in healthcare infrastructure over this region. This creates the need for developing novel, enhanced, and economic methods for production of specialty generics drugs. This factor is further anticipated boost the global specialty generic drugs market in the forecast period.

Segment Analysis

全球特色通用药物市场是在申请，行政路径，分销渠道和地区的基础上进行分割。在申请的基础上，全球特色普通药物市场被分段为肿瘤，传染病，多发性硬化症，丙型肝炎等。基于申请，肿瘤科段在2017年占据了全球市场。癌症的患病率增加，如黑素瘤，肺癌，乳腺癌，白血病，前列腺癌和结肠癌都针对全球通用特种药物的需求增加。据国际癌症研究机构（IARC）的说法，2012年，全球约有1400万癌症病例被诊断出来，这个数字预计将在未来期间上涨。因此，随着普遍性的越来越普遍，对低成本泛型药物的需求较大，与品牌药物相比，昂贵且非常有效。

在管理途径的基础上，全球市场分为口腔，肠外，局部，注射和其他人。2017年，由于效益，持续时间长期，即时剂量分布和快速吸收，可注射部分估计最大的市场份额。

在分销渠道的基础上，全球特色通用药物市场被分段为零售药房，医院药店和在线药店。2017年，医院药房估计在全球范围内分享主要市场，因为这些特种药物高度复合，昂贵，并要求非常仔细地处理。因此，这些药物通常由制造商通过医院药店分发。

Regional Analysis

By geography, the global specialty generic drugs market is segmented into five major regions, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2017, North America dominated the market with the largest share due to favorable healthcare developments by the government and a strapping healthcare infrastructure in this region. Furthermore, healthcare organizations, such as World Health Organizations (WHO), are widely involved in framing policies, such as the National Cancer Control Programs, which are anticipated to expand the growth in this region. The Asia Pacific is anticipated to dominate the global market during the forecast period. The market is driven by a rise in prevalence of chronic diseases as well as high demand for cost-effective generic drugs. In addition, a rise in per head income increases the prospect of usage of specialty generics, and continual upgradation of healthcare infrastructure is recognized to provide the market with global growth opportunities over the forecast period.

竞争分析

Some of the major key players operating in global specialty generic drugs market are Mylan N.V., Teva Pharmaceuticals USA, Inc., Sandoz International GmbH, Mallinckrodt, Akorn Inc., Valeant Pharmaceuticals International Inc., Endo Pharmaceuticals Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Apotex Corp. among others.